Reversion of patients with chronic migraine to an episodic migraine classification with fremanezumab treatment (vol 19, P7, 2018)

被引：0
|
作者：
Cohen, Joshua M. [1 ]
Bibeau, Kristen [1 ]
Galic, Maja [2 ]
Seminerio, Michael J. [1 ]
Ramirez Campos, Verena [3 ]
Singh, Rashmi B. Halker [4 ]
Ailani, Jessica [5 ]
机构：
[1] Teva Pharmaceut, Frazer, PA 19355 USA
[2] Teva Pharmaceut, Amsterdam, Netherlands
[3] Teva Pharmaceut, Buenos Aires, DF, Argentina
[4] Mayo Clin, Phoenix, AZ USA
[5] Medstar Georgetown Univ Hosp, Washington, DC USA
来源：
JOURNAL OF HEADACHE AND PAIN | 2018年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Reduction in the severity and duration of headache following fremanezumab treatment in patients with episodic and chronic migraine
    Ashina, Messoud
    Cohen, Joshua M.
    Gandhi, Sanjay K.
    Du, Evelyn
    HEADACHE, 2021, 61 (06): : 916 - 926
  • [22] Achievement of Response over Time with Fremanezumab in the Treatment of Chronic and Episodic Migraine
    Silberstein, S. D.
    Lipton, R. B.
    Diamond, M. L.
    Cohen, J. M.
    Yang, R.
    Jiang, B.
    HEADACHE, 2018, 58 (08): : 1300 - 1301
  • [23] Achievement of response over time with fremanezumab in the treatment of chronic and episodic migraine
    Silberstein, Stephen D.
    Lipton, Richard B.
    Diamond, Merle L.
    Cohen, Joshua M.
    Yang, Ronghua
    Jiang, Bo
    JOURNAL OF HEADACHE AND PAIN, 2018, 19
  • [24] Time Gained With Long-term Fremanezumab Treatment in Patients With Chronic and Episodic Migraine
    Marmura, M.
    Cohen, J. M.
    Ning, X.
    Campos, V. Ramirez
    Barash, S.
    Goadsby, P. J.
    JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 1) : 117 - 117
  • [25] Reversion from chronic to episodic migraine and clinically meaningful responses to fremanezumab in patients with inadequate response to 2-4 classes of migraine preventive medications
    Ashina, M.
    Ning, X.
    Galic, M.
    Cohen, J. M.
    Ramirez-Campos, V.
    Yang, R.
    Ailani, J.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2019, 405
  • [26] Efficacy of fremanezumab in patients with chronic migraine with or without concomitant use of preventive medication (vol 19, pg P8, 2018)
    Goadsby, Peter J.
    Dodick, David W.
    Silberstein, Stephen D.
    Yeung, Paul P.
    Blankenbiller, Tricia
    Ning, Xiaoping
    Yang, Ronghua
    Ma, Yuju
    Aycardi, Ernesto
    Bigal, Marcelo E.
    JOURNAL OF HEADACHE AND PAIN, 2018, 19
  • [27] Long-Term Efficacy of Fremanezumab in Patients Who Reverted From a Chronic to an Episodic Migraine Classification
    Lipton, Richard
    Cohen, Joshua
    Yeung, Paul P.
    Yang, Ronghua
    Seminerio, Michael
    Campos, Verena Ramirez
    Singh, Rashmi Halker
    Ailani, Jessica
    NEUROLOGY, 2019, 92 (15)
  • [28] Efficacy of fremanezumab in patients with chronic migraine and comorbid moderate to moderately severe depression (vol 19, pg P10, 2018)
    Cohen, Joshua M.
    Yeung, Paul P.
    Aycardi, Ernesto
    Bigal, Marcelo E.
    Yang, Ronghua
    Bibeau, Kristen
    Galic, Maja
    Seminerio, Michael J.
    Lipton, Richard B.
    Buse, Dawn C.
    JOURNAL OF HEADACHE AND PAIN, 2018, 19
  • [29] Improvement in Response over Time with Fremanezumab in Patients Who Reverted from a Chronic to an Episodic Migraine Classification
    Singh, R. B. Halker
    Marmura, M. J.
    Cohen, J. M.
    Yang, R.
    HEADACHE, 2019, 59 : 108 - 108
  • [30] Long-Term Efficacy of Fremanezumab in Patients Who Reverted from a Chronic to an Episodic Migraine Classification
    Lipton, R. B.
    Cohen, J. M.
    Yang, R.
    Seminerio, M. J.
    Campos, V. Ramirez
    Singh, R. B. Walker
    Ailani, J.
    HEADACHE, 2019, 59 : 101 - 102
12345